For anyone in Gacé searching for CJC-1295, the first thing to know is that this compound is available only through an online research supply market. What this means for Gacé researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those evaluation tools are available to every researcher. Separating genuine research-grade CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. What follows is a vendor evaluation and quality guide built specifically around CJC-1295, covering everything a Gacé researcher needs to source confidently.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Gacé comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
The most consistent path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums aggregate real purchasing experience that are more accurate than commercial vendor claims. A COA for CJC-1295 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Positive vendor signals beyond COA quality: documented vendor history spanning multiple years, responsive technical support who understand testing methodology, and cold chain packaging that protects product integrity. Hold lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and keep the remainder frozen.
Order CJC-1295 — ships to Gacé
COA-verified · International tracking · Research grade
All use of CJC-1295 in Gacé or anywhere constitutes research use — this compound is not approved for human therapeutic use, and all handling should adhere to research compound handling standards. Temperature excursions — even short periods above −20°C — can partially degrade CJC-1295 without any obvious sign; always maintain cold chain and work with cold-shipped material. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that verified-quality sourcing directly prevents. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
